With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

November 6, 2024MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Operator: Hello ...

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) yesterday and set a price ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD). Crispr ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...